TGA approves COVID-19 Omicron Vaccine
The Therapeutic Goods Administration (TGA) has provisionally approved Moderna's Omicron booster candidate, also known as mRNA-1273.214.
The Therapeutic Goods Administration (TGA) has given a provisional green light to Moderna’s updated COVID-19 booster vaccine for people aged 18 and over, which targets both the original strain of SARS-CoV-2 as well as the Omicron variant.
Of the vaccine dose, 25 micrograms of imelasomeran targets the BA.1 variant, while 25 micrograms of elasomeran is aimed at the original strain of SARSCoV-2.
The exact guidelines for administering the vaccine, which is the first to specifically target the variant, are expected to be confirmed by the Australian Technical Advisory Group on Immunisation (ATAGI) in the coming weeks. You can read more here.
